# The Delaware Comprehensive Sickle Cell Research Center

> **NIH NIH P20** · NEMOURS CHILDREN'S HOSPITAL, DELAWARE · 2021 · $2,064,535

## Abstract

PROJECT SUMMARY
The Delaware Sickle Cell Disease (SCD) COBRE is a multidisciplinary center of biomedical research
excellence with a thematic focus on translational, clinical and psychosocial research in sickle cell disease.
Building on a biomedical and clinical research infrastructure developed through COBRE Phase 1 funding, and
the successful recruitment of several promising early career investigators, the DE SCD COBRE is submitting a
competitive renewal application to continue capacity-building and innovative research. In Phase 1, the DE SCD
COBRE contributed to more than $13 million in new funding in Delaware. Integration of the DE SCD COBRE
within the Delaware IDeA network continues to be integral to both the successful recruitment and training of
early career investigators, as well as pilot funding. In this Phase 2 COBRE submission, the DE SCD COBRE
presents a new mentoring model, a new pilot funding program, a new Clinical Research and Data Informatics
Core and four new target investigators. Each of these new additions builds on success in Phase 1 and is
responsive to areas of strength and growth. Additionally, we developing a multidisciplinary and systematic
approach to study the influence of stigma and racism within communities and the healthcare system on the
efficacy of both routine health maintenance and targeted interventions in patients with SCD. We will evaluate
biomarkers for severe SCD co-morbidities (Project 4), engage our patients and community to take stock of
barriers to routine care (Project 1, 2, and 3) and explore tools to improve self-efficacy among health care
providers (Project 1) and patients (Project 1, 2, and 3), while simultaneously confronting how racism impacts
the health of children and young adults (Project 1, 2, and 3). Central to all aspects of the Delaware Sickle Cell
Research Program is the overarching Center hypothesis that effective management of a common,
congenital, multi-system disease requires comprehensive investigations spanning the biological, medical,
psychological, and societal factors that impact both the severity of the disease and the efficacy of interventions.

## Key facts

- **NIH application ID:** 10271040
- **Project number:** 2P20GM109021-06
- **Recipient organization:** NEMOURS CHILDREN'S HOSPITAL, DELAWARE
- **Principal Investigator:** Edward Anders Kolb
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,064,535
- **Award type:** 2
- **Project period:** 2014-08-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10271040

## Citation

> US National Institutes of Health, RePORTER application 10271040, The Delaware Comprehensive Sickle Cell Research Center (2P20GM109021-06). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10271040. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*